Metastatic clear-cell renal cell carcinoma (mccRCC) remains a major cause of morbidity and mortality among patients with kidney cancer. Over the past two decades, mccRCC treatment has significantly evolved with the incorporation of antiangiogenic tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) as the cornerstone of systemic therapy. In response, major international guidelines have continuously updated their recommendations according to emerging evidence from clinical trials. We provide an overview of current management recommendations for mccRCC, including cytoreductive nephrectomy (CN), active surveillance (AS), first-line treatment, and subsequent-line treatment. While upfront CN is no longer recommended for unselected patients, it remains an option for carefully selected patients with a limited metastatic burden. AS can be considered for those with slow-growing, asymptomatic, low-volume disease. First-line treatment strategies now prioritize ICI based combinations tailored to patient risk factors, comorbidities, and disease characteristics. In subsequent lines, treatment sequencing remains a challenge, with ongoing research needed to refine therapeutic choices. As new evidence emerges, treatment strategies must continue to adapt, underscoring the need for ongoing updates to clinical guidelines. PATIENT SUMMARY: Clinical trials are continuously identifying new treatments for advanced kidney cancer. Our guideline provides updated treatment recommendations from international societies that are based on evidence from these trials. Personalized treatment can improve the care and outcomes for patients with advanced kidney cancer.
European urology focus. 2025 May 05 [Epub ahead of print]
Regina Barragan-Carrillo, Anna Scavuzzo, Miguel Angel Jimenez-Rios, Nora Sobrevilla-Moreno
Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Department of Medical Oncology, Instituto Nacional de Cancerologia, Mexico City, Mexico. Electronic address: ., Department of Urology, Instituto Nacional de Cancerologia, Mexico City, Mexico., Department of Medical Oncology, Instituto Nacional de Cancerologia, Mexico City, Mexico.